Stay informed about the latest developments at Mand-peptide including product launches, certifications, partnerships, and industry insights.
Our manufacturing facility has successfully completed the cGMP audit by European regulatory authorities, enabling direct pharmaceutical-grade peptide exports to EU markets including Germany, France, and the Netherlands.
Mand-peptide announces expanded production capacity for weight management peptides. New lyophilization line increases output by 300% to meet surging global demand for GLP-1 analogs.
Mand-peptide signs exclusive distribution agreement covering 15 European countries. The partnership will accelerate market penetration for our cosmetic peptide portfolio and research-grade compounds.
Our R&D team publishes findings on a next-generation GHK-Cu derivative showing 40% faster wound closure in preclinical studies. Patent applications filed in US, EU, and China.
Mand-peptide implements solvent recycling program and aqueous-phase synthesis protocols, reducing organic solvent waste by 65% while maintaining 99%+ product purity standards.
Our Chief Scientific Officer delivered a keynote on scalable solid-phase peptide synthesis innovations at the IPS 2026 in Tokyo, highlighting our proprietary linker technology.